Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance

Ascendis Pharma A/STrade
JPMorgan Ultra Short Income ETFTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs JPMorgan Ultra Short Income ETF — how do they compare? Ascendis Pharma A/S trades at $257 (market cap $16.67B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

ASNDJPST
Market Cap
$16.67B
Sector
HealthLeveraged / Inverse
52-Week High
$277.18$50.78
52-Week Low
$189.74$50.40
Enterprise Value
$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.

ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.

JPMorgan Ultra Short Income ETF

JPST (JPMorgan Ultra-Short Income ETF) trades at $50.46, showing minimal daily movement with a 0.04% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent institutional filings show growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund provides regular dividend distributions, with recent payments of $0.17 per share.

As an ultra-short income ETF, JPST offers stability and income generation in a rising rate environment. The fund's conservative positioning appeals to risk-averse investors seeking cash alternatives. Key risks include interest rate sensitivity and inflationary pressures that could impact short-term bond yields. Institutional accumulation suggests confidence in the fund's strategic positioning.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST